RXST logo

RxSight, Inc. Stock Price

NasdaqGM:RXST Community·US$347.4m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

RXST Share Price Performance

US$8.28
-40.97 (-83.19%)
6.9% undervalued intrinsic discount
US$8.89
Fair Value
US$8.28
-40.97 (-83.19%)
6.9% undervalued intrinsic discount
US$8.89
Fair Value
Price US$8.28
AnalystConsensusTarget US$8.89

RXST Community Narratives

AnalystConsensusTarget·
Fair Value US$8.89 6.9% undervalued intrinsic discount

Entry Into European And Asian Markets Will Unlock New Opportunities

0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative

Recent RXST News & Updates

The Bottom Fishing Club - RxSight: A Ski-Jump Reversal Pattern?

Sep 22

Investors Don't See Light At End Of RxSight, Inc.'s (NASDAQ:RXST) Tunnel And Push Stock Down 39%

Aug 07
Investors Don't See Light At End Of RxSight, Inc.'s (NASDAQ:RXST) Tunnel And Push Stock Down 39%

Time To Worry? Analysts Just Downgraded Their RxSight, Inc. (NASDAQ:RXST) Outlook

Jul 19
Time To Worry? Analysts Just Downgraded Their RxSight, Inc. (NASDAQ:RXST) Outlook

The Price Is Right For RxSight, Inc. (NASDAQ:RXST)

Jun 18
The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
User avatar

South Korea And UK Approvals Will Expand Market Adoption

International expansion and regulatory approvals are poised to significantly boost revenue by entering new markets and enhancing clinical support.

RxSight, Inc. Key Details

US$147.1m

Revenue

US$39.5m

Cost of Revenue

US$107.5m

Gross Profit

US$139.8m

Other Expenses

-US$32.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.79
Gross Margin
73.12%
Net Profit Margin
-21.93%
Debt/Equity Ratio
0%

RxSight, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet with low risk.

3 Risks
0 Rewards

About RXST

Founded
1997
Employees
498
CEO
Ronald Kurtz
WebsiteView website
www.rxsight.com

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 0.4%
  • 3 Months: 7.8%
  • 1 Year: 17.8%
  • Year to Date: 14.7%
The Healthcare sector gained 3.7% while the market remained flat over the last week. More promisingly, the market is up 18% over the past year. Earnings are forecast to grow by 15% annually. Market details ›